August 1, 2026  |   Read time: 6 mins

Beth Wright

‍

‍

Lung cancer kills more people every year than colon, breast, and liver cancer combined [1].

That fact alone is why World Lung Cancer Day exists, pushing for more research funding and better public understanding of a disease that carries many outdated assumptions.

Lung cancer in 2026 doesn't look like lung cancer did even a decade ago. Who gets it, why, and what happens next have all shifted.

The basics: it's not simply one disease

"Lung cancer" is really an umbrella term for two biologically distinct diseases that happen to start in the same organ.

• Non-small cell lung cancer (NSCLC) makes up around 85% of cases. It's further split into subtypes, adenocarcinoma (the most common, and increasingly the one seen in non-smokers), squamous cell carcinoma, and large cell carcinoma, each with different cell origins and behaviour.
• Small cell lung cancer (SCLC) is less common but grows faster and spreads earlier. It's almost always tied to heavy smoking history, though its treatment landscape is also shifting fast, which we'll get to.

Globally, the World Health Organization estimated 2.5 million new cases and 1.8 million deaths in 2022 [1], making lung cancer both the most-diagnosed and most-deadly cancer worldwide.

A growing non-smoking population of lung cancer patients

Overall lung cancer incidence is falling in step with declining smoking rates in many countries [https://www.who.int/news/item/16-01-2024-tobacco-use-declines-despite-tobacco-industry-efforts-to-jeopardize-progress]. But a distinct and separate trend is emerging inside that overall decline: a rising share of cases in people who have never smoked.

In the United States, an estimated 10-20% of lung cancers now occur in never-smokers, up from around 8% in the early 1990s [https://www.cdc.gov/lung-cancer/nonsmokers/index.html2]. In parts of Asia, the picture is even more pronounced: in China, roughly 86% of lung cancers in women and 45% in men are diagnosed in people who've never smoked [3]. Some researchers now rank lung cancer in never-smokers as its own major cause of cancer death [4-8].

Two things seem to be happening simultaneously:

1. Smoking-related cases are dropping, and
2. Non-smoking-related cases aren't dropping at the same rate… in some populations, they're rising

The result is a changing denominator, and a diagnostic blind spot, since screening programs are built almost entirely around smoking history [4-8].

Who lung cancer looks like now: sex disparities and the incidental finding

Alongside the never-smoker trend, two other patterns are drawing attention: an earlier age of onset in some populations, and a disproportionate share of cases in women.

Rising rates of early-onset disease have been reported in population studies from Singapore and China, particularly among women. Comparable trends have also been observed in the United States, where diagnoses are increasing among specific populations, including Asian women, with possible increases among Hispanic women [9-11].

Globally, women account for roughly two-thirds of never-smokers diagnosed with the disease, for reasons that remain unclear.

Current thinking points to a tangle of contributors: household and ambient air pollution, occupational exposures, genetic susceptibility, differences in tumour biology, and better detection through chest imaging performed for other reasons.

That last point deserves care, because detection is not the same as disease.

In a South Korean cohort of 21,062 people with no smoking history who underwent opportunistic low-dose CT screening, 176 lung cancers were detected. Of these, 93.2% were stage 0 or stage I, 96% were adenocarcinoma spectrum disease, and five-year lung cancer specific survival was 97.7% in women and 100% in men, with no statistically significant difference by sex for any outcome [12]. The authors' conclusion was not that screening favours one sex, but that men and women with no smoking history experience a similar risk of overdiagnosis, with limited benefit, when screening is applied indiscriminately.

The same study is candid about what it could not measure. Data on exposures such as air pollution, occupational factors and second-hand smoke were unavailable, so the analysis cannot speak to what actually drove the cancers it found [12].

A disease still widely pictured as belonging to older male lifelong smokers is increasingly diagnosed in people who do not fit that description at all.

Yet, when neither patient nor clinician is looking for it, a persistent cough or breathlessness can be attributed to something else, and the diagnosis arrives later, past the point where curative treatment is an option [13].

The stakes are not marginal: lung cancer is the leading cause of cancer death among women in the United States, with an estimated 61,950 female deaths in 2026, taking as many lives as breast, ovarian and cervical cancers combined [14]. Closing this gap will take work at two levels: better exposure data at population scale, and a clearer picture of the sex-specific cellular processes that make the same lung respond differently to the same injury[10].

How smoking actually causes lung cancer, and why never-smokers' tumours are different

Cigarette smoke is not one poison but thousands. Burning tobacco produces more than 7,000 different chemicals, and at least 70 of them are established causes of cancer in humans [15,16].

Every inhalation damages the DNA inside the cells lining the airways.

A single hit is usually repaired. Sustained exposure, year after year, overwhelms the repair machinery, and the damage starts to stick [17].

The damage from smoking has a pattern.

Different chemicals break DNA in characteristically different ways, and those patterns can be read back out of a tumour's genome years later, rather like handwriting. Researchers call them mutational signatures, and one particularly linked to tobacco smoke is known as SBS4 [18].

Intriguingly, SBS4 is largely missing from the tumours of people who have never smoked.

In the largest study of its kind, which sequenced the complete tumour genomes of 871 never-smokers from 28 locations worldwide, the tobacco signature appeared in fewer than 5% of lung adenocarcinomas [19]. The signature is reliable enough that researchers use it as a check on their own data, even picking up individuals mislabelled in trials as current vs never-smokers [20].

So when the signature is absent across hundreds of cases, it is strong evidence that these cancers are not simply undisclosed smoking.

Smoking-related tumours are more likely to carry damage to TP53, a gene whose normal job is to halt a cell that has become dangerous, a sort of emergency brake [19,21]. Never-smoker tumours more often carry a different kind of muttaion, a 'driver mutation', a single stuck accelerator in a gene such as EGFR or ALK.

That distinction matters clinically, because a stuck accelerator is something a drug can target. In one analysis of over 900 patients with lung adenocarcinoma, 85% of never-smokers had an identifiable driver mutation, and 71% had one for which an approved drug already exists. Among smokers, 65% had a driver mutation, and far fewer of those were treatable with a targeted drug [22].

A broken emergency brake, by contrast, is much harder to fix with a tablet, because restoring a lost function is a harder pharmacological problem than blocking an overactive one.

So the same organ, the same diagnosis on paper, and two different diseases underneath. That is what is reshaping treatment, and it is the most hopeful part of this story.

The causes of lung cancer go beyond smoking

Smoking remains the dominant risk factor by a wide margin, but it is not the only one. The established list runs well past tobacco.

Radon gas: A naturally occurring radioactive gas from soil and rock that seeps into buildings. It's the leading cause of lung cancer in never-smokers in some estimates.

Air pollution: Both outdoor (fine particulate matter, PM2.5) and household (solid fuel cooking and heating).

Occupational exposures: Asbestos, silica dust, and diesel exhaust among them.

Second-hand smoke: A weaker but real carcinogen; passive exposure raises risk by roughly 20–24%, though it only explains a minority of never-smoker cases.

Genetic susceptibility and inherited mutations: Can raise baseline risk independent of any exposure at all.

None of these carry the same population-level weight as active smoking. Together, though, they explain why a meaningful share of patients arrive at diagnosis with no smoking history and no obvious explanation.

The most hopeful pattern: treatment is genuinely improving

Here's the shift that deserves more attention than it usually gets: five-year survival for lung cancer in the US has climbed from roughly 18% to nearly 30% over the past eight years, according to the American Lung Association's 2025 State of Lung Cancer report, one of the largest survival gains of any solid tumour in that timeframe [23].

The trajectory is real, and it's a rare enough thing in oncology that it's worth saying plainly: for a growing number of patients, this disease is becoming more survivable, not less.

The takeaway

Lung cancer in 2026 is being reshaped from two directions at once, a shrinking pool of smoking-related cases, and a distinct, biologically different, and not-yet-fully-understood rise in cases among people who've never smoked.

Add in real, measurable gains in treatment, and the honest picture is more complicated, and more hopeful, than the old "smoker's disease" framing allows for.

‍

‍

‍

References

1. World Health Organization, Lung cancer fact sheet (16 April 2026)
2. CDC, Lung Cancer Among People Who Never Smoked (2026). https://www.cdc.gov/lung-cancer/nonsmokers/index.html
3. Zheng W, Jiang G, Wang C, et al. Comparative study of lung cancer between smokers and nonsmokers: A real-world study based on the whole population from Tianjin City, China. Tobacco Induced Diseases. 2024;22(September):154. doi:10.18332/tid/192191.
4. See KC. Lung cancer screening for never smokers: current evidence and future directions. Singapore Med J. 2026 Jan 1;67(1):3-10. doi: 10.4103/singaporemedj.SMJ-2023-007. Epub 2024 Jan 16. PMID: 38240131; PMCID: PMC12908900.  https://doi.org/10.4103/singaporemedj.SMJ-2023-007
5. Kakinuma R, Muramatsu Y, Asamura H, Watanabe SI, Kusumoto M, Tsuchida T, Kaneko M, Tsuta K, Maeshima AM, Ishii G, Nagai K, Yamaji T, Matsuda T, Moriyama N. Low-dose CT lung cancer screening in never-smokers and smokers: results of an eight-year observational study. Transl Lung Cancer Res. 2020 Feb;9(1):10-22. doi: 10.21037/tlcr.2020.01.13. PMID: 32206549; PMCID: PMC7082286.
6. https://www.nih.gov/news-events/nih-research-matters/factors-linked-lung-cancer-never-smokers
7. Forbes, "Lung Cancer Rising Among Never-Smokers" (Feb 2026)
8. Trends in Cancer, "Lung cancer in never smokers: from early detection to prevention" (2026)
9. Ragavan, M. V., & Patel, M. I. (2020). Understanding sex disparities in lung cancer incidence: are women more at risk?. Lung cancer management, 9(3), LMT34. https://doi.org/10.2217/lmt-2020-0013
10. Ratnakaram, K., Yendamuri, S., Groman, A., & Kalvapudi, S. (2024). Sex-Based Differences in Lung Cancer Incidence: A Retrospective Analysis of Two Large US-Based Cancer Databases. Cancers, 16(19), 3244. https://doi.org/10.3390/cancers16193244
11. Juang, Y. R., Hu, M., Hui, M., Seow, A., Tan, I. B. H., Chong, D. Q., Chee, C. E., & Seow, W. J. (2025). Trends in lung cancer incidence and stage at diagnosis in Singapore: a population-based joinpoint regression analysis by age, sex, and smoking status. The Lancet regional health. Western Pacific, 66, 101779. https://doi.org/10.1016/j.lanwpc.2025.101779
12. Kim, Y. W., Joo, D. H., Kim, S. Y., Park, Y. S., Jang, S., Lee, J. H., Silvestri, G. A., Heuvelmans, M. A., Kim, J., Hwang, H., & Lee, C. T. (2025). Gender Disparities and Lung Cancer Screening Outcomes Among Individuals Who Have Never Smoked. JAMA network open, 8(1), e2454057. https://doi.org/10.1001/jamanetworkopen.2024.54057
13. Florez, N., Kiel, L., Riano, I., Patel, S., DeCarli, K., Dhawan, N., Franco, I., Odai-Afotey, A., Meza, K., Swami, N., Patel, J., & Sequist, L. V. (2024). Lung cancer in women: The past, present, and future. Clinical Lung Cancer, 25(1), 1–8. https://doi.org/10.1016/j.cllc.2023.10.007
14. Lungcancerresearchfoundation
15. National Academies of Sciences, Engineering, and Medicine. (2018). Public health consequences of e-cigarettes. The National Academies Press. https://doi.org/10.17226/24952
16. American Cancer Society. (n.d.). Harmful chemicals in tobacco products. https://www.cancer.org/cancer/risk-prevention/tobacco/carcinogens-found-in-tobacco-products.html
17. Centers for Disease Control and Prevention. (2024). Health effects of cigarettes: Cancer. https://www.cdc.gov/tobacco/about/cigarettes-and-cancer.html
18. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., . . . Stratton, M. R. (2013). Signatures of mutational processes in human cancer. Nature, 500(7463), 415–421. https://doi.org/10.1038/nature12477
19. Díaz-Gay, M., Zhang, T., Hoang, P. H., Leduc, C., Baine, M. K., Travis, W. D., . . . Landi, M. T. (2025). The mutagenic forces shaping the genomes of lung cancer in never smokers. Nature, 644(8075), 133–144. https://doi.org/10.1038/s41586-025-09219-0
20. Landi, M. T., Synnott, N. C., Rosenbaum, J., Zhang, T., Zhu, B., Shi, J., . . . Chanock, S. J. (2021). Tracing lung cancer risk factors through mutational signatures in never-smokers: The Sherlock-Lung study. American Journal of Epidemiology, 190(6), 962–976. https://doi.org/10.1093/aje/kwaa234
21. U.S. Department of Health and Human Services. (2010). How tobacco smoke causes disease: The biology and behavioral basis for smoking-attributable disease. Centers for Disease Control and Prevention. https://www.ncbi.nlm.nih.gov/books/NBK53010/
22. Mack, P. C., Klein, M. I., Ayers, K. L., Zhou, X., Guin, S., Fink, M., . . . Hirsch, F. R. (2022). Targeted next-generation sequencing reveals exceptionally high rates of molecular driver mutations in never-smokers with lung adenocarcinoma. The Oncologist, 27(6), 476–486. https://doi.org/10.1093/oncolo/oyac035
23. Association, A. L. (n.d.). New report: Lung cancer advancements are saving more lives than ever, but funding cuts may hinder progress. https://www.lung.org/media/press-releases/fy26-solc-national